CGS 35601

a single molecule triple vasopeptidase inhibitor; structure in first source

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

1.	Type 2 Diabetes Mellitus (MODY) 01/01/2005 - "The antihypertensive efficacy of CGS 35601 was demonstrated in chronically instrumented, unrestrained and conscious rat models of hypertension (SHR and DSS) and type 2 diabetes (ZDF-fatty). " 06/01/2006 - "CGS 35601 is a triple vasopeptidase inhibitor (VPI) of angiotensin converting enzyme (ACE), neutral endopeptidase (NEP), and endothelin (ET) converting enzyme-1 (ECE-1), with respective IC(50) values of 22, 2, and 55 nM. The aim of the present study was to establish the hemodynamic profile of Zucker diabetic fatty (Zdf)-Fatty rats, a high-fat diet gene-prone model developing spontaneous Type 2 diabetes (T2D) and the effects of CGS 35601. "
2.	Hypertension (High Blood Pressure) 01/01/2005 - "The antihypertensive efficacy of CGS 35601 was demonstrated in chronically instrumented, unrestrained and conscious rat models of hypertension (SHR and DSS) and type 2 diabetes (ZDF-fatty). " 06/01/2006 - "Triple VPI CGS 35601 reduces high blood pressure in low-renin, high-salt Dahl salt-sensitive rats."

1.	Antihypertensive Agents (Antihypertensives)
2.	Endothelins (Endothelin)
3.	Neprilysin (Neutral Endopeptidase)
4.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
5.	Vasopeptidase Inhibitors
6.	Salts
7.	Renin